Coronary Artery Disease (CAD)

Safety and efficacy of the latest generation biodegradable polymer-coated ultrathin sirolimus-eluting stent in the treatment of coronary artery disease in a European all-comer population with or without high bleeding risk: The Cruz HBR Registry

- Coronary Artery Disease (CAD) - Minerva Cardiology and Angiology

One-month DAPT after biodegradable-polymer everolimus-eluting stent implantation in patients at high-bleeding risk: an individual patient data pooled analysis of the SENIOR and POEM trials

- Coronary Artery Disease (CAD) - European Heart Journal

Comparison of Ultrathin- Versus Thin-Strut Stents in Patients With High Bleeding Risk PCI: Results From the COMPARE 60/80 HBR Trial: An Open-Label, Randomized, Controlled Trial

- Coronary Artery Disease (CAD) - Circulation

TCT-381 Safety and Effectiveness of a Novel Intravascular Lithotripsy Device Using the Hertz Contact Stress Mechanism for Calcium Fragmentation: Six-Month Outcomes of the PINNACLE I Clinical Trial

- Coronary Artery Disease (CAD) - Journal of the American College of Cardiology (JACC)

Bioadaptor implant versus contemporary drug-eluting stent in percutaneous coronary interventions in Sweden (INFINITY-SWEDEHEART): a single-blind, non-inferiority, registry-based, randomised controlled trial.

- Coronary Artery Disease (CAD) - The Lancet

One-month DAPT after biodegradable-polymer everolimus-eluting stent implantation in women at high-bleeding risk: Insights from the POEM trial

- Coronary Artery Disease (CAD) - Catheterization & Cardiovascular Interventions (CCI)

Rationale and design of INFINITY-SWEDEHEART: A registry-based randomized clinical trial comparing clinical outcomes of the sirolimus-eluting DynamX bioadaptor to the zotarolimus-eluting Resolute Onyx stent.

- Coronary Artery Disease (CAD) - American Heart Journal

Abbreviated or Standard Antiplatelet Therapy After PCI in Diabetic Patients at High Bleeding Risk

- Coronary Artery Disease (CAD) - Journal of the American College of Cardiology (JACC)

Benefit of coronary stenting using available intracoronary tools in high-risk patients. The OPTI-XIENCE study

- Coronary Artery Disease (CAD) - International Journal of Cardiology

TCT-245 Final 7-Year Results from the COMPARE-ABSORB Trial: Randomized Comparison of Bioresorbable Vascular Scaffold Versus Metallic Drug-Eluting Stent in Patients at High Risk of Restenosis. Detailed analysis of long lesions

- Coronary Artery Disease (CAD) - Journal of the American College of Cardiology (JACC)